Galecto

An artists depiction of different types of blood cells from bone marrow

Galecto posts myelofibrosis data as search for savior continues

Three months into a review of strategic alternatives, the biotech has posted results from a phase 2a trial of a potential treatment for myelofibrosis.

Nick Paul Taylor Dec 22, 2023 6:50am

Galecto lays off 70% in wake of fibrosis drug's phase 2 fail

Sep 27, 2023 7:50am

plan B fail reroute road path trail miss

Galecto cans lung fibrosis med after ph. 2 fail, pivots to liver

Aug 15, 2023 7:30am

Galecto travels deeper into liver disease with GULLIVER-2 data

Nov 8, 2022 10:35am

Galecto links blood cancer prospect to reduced fibrosis

Sep 29, 2022 9:20am

Galecto bags $64M to push lung fibrosis med toward EU nod

Sep 25, 2020 10:04am